Showing results (441-450 of 607) with videos related to

Sort By:
Pageof 61
Pharmacoeconomics - Open|February 4, 2018
Utilization and Expenditure of Anti-cancer Medicines in Kosovo: Findings and ImplicationsArianit Jakupi, Brian Godman, Antony Martin, et al.
Pharmacoeconomics - Open|February 22, 2018
Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm InfantsAhva Shahabi, Desi Peneva, Devin Incerti, et al.
Pharmacoeconomics - Open|February 22, 2018
Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims DataJacqueline Nicholas, Aaron Boster, Ning Wu, et al.
Pharmacoeconomics - Open|February 23, 2018
Longitudinal Effects of Adjuvant Endocrine Therapy on the Quality of Life of Post-menopausal Women with Non-metastatic ER+ Breast Cancer: A Systematic ReviewHong Xiao, Xinyi Jiang, Cheng Chen, et al.
Pharmacoeconomics - Open|February 15, 2018
Health System Efficiency: A Fragmented Picture Based on OECD DataAndreas Behr, Katja Theune
Pharmacoeconomics - Open|February 15, 2018
Choosing Between Unicompartmental and Total Knee Replacement: What Can Economic Evaluations Tell Us? A Systematic ReviewEdward Burn, Alexander D Liddle, Thomas W Hamilton, et al.
Pharmacoeconomics - Open|April 29, 2021
Cost-effectiveness of a Province-wide Quality Improvement Initiative for Reducing Potentially Inappropriate Use of Antipsychotics in Long-Term Care in British Columbia, CanadaAsif Raza Khowaja, Christina Krause, Colleen Kennedy, et al.
Pharmacoeconomics - Open|April 16, 2020
Economic Burden of Chronic Obstructive Pulmonary Disease Patients in Malaysia: A Longitudinal StudyAnees Ur Rehman, Mohamed Azmi Ahmad Hassali, Sohail Ayaz Muhammad, et al.
Pharmacoeconomics - Open|August 4, 2022
Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)Lotte Westerink, Jelmer Lennart Jens Nicolai, Maarten Jacobus Postma, et al.
Pharmacoeconomics - Open|September 17, 2021
Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare PerspectiveWill Dunlop, Marjolijn van Keep, Peter Elroy, et al.
Pageof 61